TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03911245

Intervention type: OTHER
Intervention: Retrospective study. Analyze of data in medical records
Description: Retrospective study. Analyze of data in medical records

Intervention type: OTHER
Intervention: Retrospective study. Analyze of data in medical records
Description: Retrospective study. Analyze of data in medical records
Study: NCT03015974

Intervention type: DRUG
Intervention: Corticosteroid
Study: NCT01342666

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cucumber consumption
Description: Daily consumption of 300g of cucumber.
Study: NCT04818710

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: skin incision with a scalpel
Description: A Pfannenstiel skin incision was done through the subcutaneous tissue, rectus sheath and dissected from rectus muscle until peritoneum was visualized.~group 1 (skin incision with a scalpel)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin incision with diathermy
Description: A Pfannenstiel skin incision was done through the subcutaneous tissue, rectus sheath and dissected from rectus muscle until peritoneum was visualized.~group 2 (skin incision with diathermy)
Study: NCT00414310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 50 mg/kg orally daily for 7 days
Study: NCT03209544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online self-help intervention
Description: The intervention was originally developed by van Spijker, van Straten, and Kerkhof (2010). For this study, it was adapted to the Flemish context and called Think Life. Think Life is mainly based Cognitive Behaviour Therapy (CBT). Additionally, it encompasses elements from Dialectical Behaviour Therapy (DBT), Problem Solving Therapy (PST), and Mindfulness Based Cognitive Therapy (MBCT). It encompasses six modules and every module starts with a psycho-educational section followed by a weekly assignment, core exercises and optional exercises. The participant weekly receives access to a new module. A more detailed description of the intervention is described elsewhere (Kerkhof, van Spijker, \& Mokkenstorm, 2013; van Spijker et al., 2010; van Spijker, van Straten, et al., 2014).
Study: NCT00333268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Next Generation Ophthalmic Irrigating Solution (NGOIS)
Description: Volume sufficient to irrigate adequately during cataract surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BSS Plus
Description: Volume sufficient to irrigate adequately during cataract surgery
Study: NCT04422665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Single-legged resistance exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Single-legged resistance exercise
Study: NCT04177056

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients will received a single fraction of 15-20 Gy to bone metastases causing pain. Planning and delivery will be conducted using a volumetric modulated arc therapy (VMAT) approach on the Varian TrueBeam platform. Patients will be CT simulated, with vac-lock immobilization. Use of 4-dimensional CT will be dependent on the area being treated. Daily image guidance will be performed using cone beam CT aligning to relevant bony anatomy.
Study: NCT04008433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Advanced intravenous injection of lidocaine before the propofol injection
Study: NCT02222012

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single channel Multiway Coil®
Description: During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two channels Multiway stimulator coil® (Brainsway Ltd.)
Description: During the two channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks).
Study: NCT03015974

Intervention type: DRUG
Intervention: Corticosteroid

Intervention type: DRUG
Intervention: Corticosteroid
Study: NCT03000816

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients with 1-4 metastases located in less than 2 organs/ lymphatic drainage regions that are 5 cm or less from each other and simultaneously treated with SBRT.
Study: NCT03977727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fiasp®
Description: Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fiasp®
Description: Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolog®
Description: Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolog®
Description: Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 670G hybrid closed loop continuous subcutaneous insulin infusion system
Description: CSII

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 670G hybrid closed loop continuous subcutaneous insulin infusion system
Description: CSII
Study: NCT00374153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Online personal feedback report

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview with Feedback
Description: In-person Motivational Interview with personal feedback report

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: In-person Motivational Interview only (without a personal feedback report)
Study: NCT03252704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistant starch (high fiber muffin top)
Description: Muffin top contained 11 g of fiber per portion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistant starch (high fiber muffin top)
Description: Muffin top contained 11 g of fiber per portion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control (low fiber muffin top)
Description: Muffin top contained 1 g of fiber per portion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control (low fiber muffin top)
Description: Muffin top contained 1 g of fiber per portion
Study: NCT03072719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride
Description: Test dentifrice, participants will brush each of the 2 selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Monofluorophosphate
Description: Control dentifrice, participants will brush the whole mouth thoroughly for at least 1 minute.
Study: NCT01199263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: Given IV
Study: NCT02403193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-509_80 mg
Description: PBF-509: 80 mg, PO, twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-509_160 mg
Description: PBF-509: 160 mg, PO, twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-509_320 mg
Description: PBF-509: 320 mg, PO, twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-509_640 mg
Description: PBF-509: 640 mg, PO, twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combo PBF-509 (160 mg) + PDR001
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combo PBF-509 (320 mg) + PDR001
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combo PBF-509 (640 mg) + PDR001
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
Study: NCT03015974

Intervention type: DRUG
Intervention: Cyclophosphamide
Study: NCT02403193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP2D (PBF-509+PDR001)_immuno naïve
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: RP2D (PBF-509+PDR001)_immuno treated
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
Study: NCT04019093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
Study: NCT03015974

Intervention type: DRUG
Intervention: Mycophenolate mofetil

Intervention type: DRUG
Intervention: Dipyridamole

Intervention type: DRUG
Intervention: Dipyridamole

Intervention type: DRUG
Intervention: Dipyridamole

Intervention type: DRUG
Intervention: ACE Inhibitor or Angiotensin receptor antagonist
Study: NCT04019093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A beverage that does not meaningfully increase breath alcohol concentration.
Study: NCT03015974

Intervention type: DRUG
Intervention: ACE Inhibitor or Angiotensin receptor antagonist
Study: NCT04561635

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple-micronutrients supplement
Description: Multiple-micronutrients supplement with 15 micronutrients
Study: NCT02756390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBTI-CS
Description: CBTI-CS is a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia. Cognitive factors are addressed via cognitive restructuring and psychoeducation. Behavioral factors are addressed by structured sleep restriction, stimulus control and sleep hygiene techniques. Cancer treatment late-effects affecting sleep are addressed as potential contributors to these cognitive and behavioral factors, and as symptoms that may benefit from referral for medical evaluation/management. Participants are instructed in these cognitive-behavioral strategies as a group, but using analysis of personal sleep-log data, symptom self-reports and targeted workbook exercises, they are helped to tailor the intervention to address their specific needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene
Description: Education on health behaviors, sleep habits and environmental practices intended to promote good quality sleep. Recommendations target exercise and natural light exposure,use of stimulants and alcohol, daytime napping, timing of meals, creating a comfortable non-stimulating sleep space, and creating sleep rituals.
Study: NCT02907593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide in Calfactant
Description: Budesonide in Calfactant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide in Calfactant
Description: Budesonide in Calfactant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide in Calfactant
Description: Budesonide in Calfactant
Study: NCT02756390

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBTI-CS via Telehealth
Description: The CBTI-CS intervention, a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia, will be administered via live video. conferencing. Participants will have a single in-person training session and subsequent CBTI-CS group sessions will be conducted by live video conference.
Study: NCT01743963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision support
Description: Clinical pharmacists mediated computerized decision support
Study: NCT02907593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide in Calfactant
Description: Budesonide in Calfactant
Study: NCT05395949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conservative treatment
Description: Prednisone 30 mg/day, supplemented with calcium and omeprazole, and Prednisone were slowly reduced to 10 mg/day after symptoms were relieved, and combined with 7.5 mg/week MTX therapy.
Study: NCT02169102

Intervention type: OTHER
Group type: OTHER
Intervention: No additional Intervention (control)
Description: No additional intervention previously to the urgency endodontic treatment (Control)

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Sham Laser Irradiation
Description: Fifteen minutes previously the urgency endodontic treatment, sham laser irradiation was performed in the tooth with irreversible inflammation in pulp.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser 1 (at 0,16 Joules/point of irradiation)
Description: Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 0,16 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser 2 (1,6 Joules/point of irradiation)
Description: Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 1,6 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
Study: NCT00652119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Cycle 1 = 60 mg/m\^2 IV weekly over 1 hour x 3 weeks; Cycles 2-6 = 60 mg/m\^2 IP weekly over 1 hour x 3 weeks of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Cycle 1 = AUC 6 IV over 1 hour on day 1; Cycles 2-6 = AUC 6 IP over 1 hour on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Cycle 2 = 15 mg/kg IV over 90 minutes on day 8; Cycles 3-6 = 15 mg/kg IV on day 1 of each cycle.
Study: NCT02780245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: At 20 minutes preoperatively, TXA of 20 mg/kg was administered in Z Solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Uterine Cooling
Description: Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
Study: NCT02864095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid (TXA)
Description: IV and topical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Description: IV and topical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Description: IV and topical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Study: NCT01363362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Laser Trabeculoplasty
Description: 360° selective laser trabeculoplasty, 100 non-overlapping spots, energy 0,5-1,2 mJ
Study: NCT01524536

Intervention type: DRUG
Group type: OTHER
Intervention: prednisone
Description: Glucocorticoids (GC) are considered the first- line therapy for hypereosinophilic syndrome.
Study: NCT04176458

Intervention type: DEVICE
Group type: OTHER
Intervention: Methacetin Breath Test (MBT)
Description: The hypothesis is that MBT CPDR 20 in the Fontan patient is abnormal as a result of alterations in liver perfusion, liver cell metabolic capability and transhepatic resistance secondary to hemodynamics unique to the Fontan as well as end-organ liver damage. Due to lack of robust biomarkers or other risk stratification schemes, we aim to determine whether there is prognostic value in hepatic MBT CPDR 20 in the Fontan patient.
Study: NCT01188252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roniciclib (BAY1000394)
Description: Oral administration twice daily in a 3 days on / 4 days off schedule. Starting dose will be 0.3 mg corresponding to approximately 0.005 mg/kg and dose will be escalated dependent on any dose limiting toxicities.
Study: NCT02260310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weizhong and Huantiao

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A-shi point
Study: NCT01457560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib (Infanrix hexa™)
Description: Three doses administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPV
Description: One dose administered orally
Study: NCT02740530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim® Rapid 2 machine
Description: See Arms description

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Magstim® Rapid 2 machine
Description: See Arms description
Study: NCT01910636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing according to the approved Copegus labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
Study: NCT00844571

Intervention type: OTHER
Intervention: E-learning program
Description: Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
Study: NCT03008499

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-activity natural killer
Description: Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
Study: NCT03035045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study: NCT06081231

Intervention type: DEVICE
Intervention: open-source APS;
Description: a continuous glucose monitoring system, an insulin pump, and an intelligent algorithm.
Study: NCT02888249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altered composition cigarette
Description: This double-blind study will systematically determine the abuse liability of altered composition cigarettes using a behavioral economics abuse-liability approach. Altered composition cigarettes (e.g., cigarettes differing in casings, sugars, tar levels, moisture) may result in decreased intake and decreased dependence, although critical questions remain regarding the abuse-liability of altered composition cigarettes, whether exposure to these cigarettes reduces use, and whether altered composition cigarettes will substitute for standard cigarettes. The addictive effects and abuse liability of altered composition cigarettes, therefore, are not well understood, and will be tested in this study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altered composition cigarette
Description: This double-blind study will systematically determine the abuse liability of altered composition cigarettes using a behavioral economics abuse-liability approach. Altered composition cigarettes (e.g., cigarettes differing in casings, sugars, tar levels, moisture) may result in decreased intake and decreased dependence, although critical questions remain regarding the abuse-liability of altered composition cigarettes, whether exposure to these cigarettes reduces use, and whether altered composition cigarettes will substitute for standard cigarettes. The addictive effects and abuse liability of altered composition cigarettes, therefore, are not well understood, and will be tested in this study.
Study: NCT04025138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Measure of supraspinal activation level and cortical excitation by Transcranial Magnetic Stimulation (TMS).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Measure of supraspinal activation level and cortical excitation by Transcranial Magnetic Stimulation (TMS).
Study: NCT02854761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)
Study: NCT04025138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Measure of supraspinal activation level and cortical excitation by Transcranial Magnetic Stimulation (TMS).